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Summary
The translational sciences aim to transfer results from basic research to the treatment of animals 
or patients. One of the approaches that could be utilized to achieve this goal is the in vitro-in vivo 
extrapolation (IVIVE) of pharmacokinetic (PK) and pharmacodynamic (PD) properties using in silico 
methods. Such methodology, if properly applied, could help substantially reduce the use of animals in  
pre-clinical research. Here, quinidine was chosen as an example of a drug with cardiac effects and results  
of nine published clinical studies describing its PK (plasma concentration) and PD (QTcB/ΔQTcB)  
effects were mimicked by combination of the IVIVE platform Simcyp (pharmacokinetics prediction) with  
the ToxComp (cardiac effect prediction) system, based exclusively on in vitro data. The results show  
that reliable QT prediction is possible using the mechanistic IVIVE of the PK and PD effects. This can be 
considered a proof-of-concept that also could be applied as a drug safety evaluation procedure.
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concepts of PK and PD mechanistic modeling and simulation 
to highlight the importance of assessing drug effect and safety 
in the preliminary phases of the drug development process. 
the IVIVe application approach necessitates the provision of 
three data sets: 1) drug related (ADMe processes and activity), 
2) system data (describing population and variability of the cho-
sen parameters), and 3) simulated trial design (Rostami-Hodjegan 
and tucker, 2007). the IVIVe methodology is a robust evalua-
tion tool that assesses inter-individual variability based on the vir-
tual population characteristics in the population study group.
to assess the application value of the described approach, 
quinidine was selected as the model drug in the virtual study 
described here. the study endpoints covered plasma concen-
tration of the parent compound and its main metabolite, 3-OH 
quinidine, from the pharmacokinetic side. either Qtc interval 
or the drug triggered change as compared to the baseline (ΔQT/
ΔQTc) were used as the pharmacodynamic effect descriptors. 
this pharmacodynamic effect dictates that drug cardiac safety 
should be regarded as a pivotal focal point of this study. Pre-
clinical studies routinely use in vitro approaches to assess car-
diac safety; however, non-rodent species (e.g., dogs, monkeys) 
are commonly used in the assessment procedure. this study 
proposes a novel concept based on a combination of mechanis-
tic PBPK/PD modeling and simulation to predict the cardiac 
effects of drugs and thus help to incorporate the 3Rs concept 
1  Introduction
the scope of translational science ranges from a general de-
scription of the drug and medical device development process 
from bench to bedside, through translating research into prac-
tice, culminating in the complex approach where the multidis-
ciplinary collaboration of translational science accelerates the 
specific scientific application (Woolf, 2008; Zerhouni, 2005). 
translational science divides the drug development process 
into a series of incremental steps1. Regardless of the transla-
tional step under consideration, all the stages contribute to a 
more effective use of the available information, and thus an 
efficient transfer of the developed therapies from the bench to 
the bedside. 
In vitro-in vivo extrapolation (IVIVe) of pharmacokinetic 
(PK) and pharmacodynamic (PD) properties of a drug by in silico 
methods provides a model-based drug development method that 
facilitates progression to the bedside endpoint (lalonde et al., 
2007). the PK and PD models used in this study are mechanistic 
models working exclusively on the in vitro data, and therefore 
no clinical study data was used at the results simulation level 
to fit parameters and improve the prediction. The mechanistic 
models are widely utilized in the “PK arena” and are becoming 
more prominent in the “PD arena” and vital areas of toxicology 
and drug safety (Marshall et al., 2006). this study unites the 
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into practice, either by waiving or reducing animal studies.
the aim of this study was to use available in vitro data ex-
clusively to simulate the in vivo effects of drugs. Both arms of 
a clinical study, i.e., pharmacokinetics and pharmacodynamics, 
were mimicked. the focus of the study was to assess the inter-
individual variability and to establish an accurate simulation 
methodology.
2  Materials and methods
Data
A wide literature search to find papers describing combined 
pharmacokinetic and pharmacodynamic effects of quinidine 
was performed. the study inclusion criteria were: a) healthy 
Caucasian volunteers, b) availability of information about the 
quinidine pharmacokinetics, ideally presented as a drug plasma 
concentration change in time, c) PD results presented as Qt/
QTc or ΔQT/ΔQTc (regardless of the correction type), thus 
comparable with the simulation outputs. Nine papers fulfilling 
such conditions were identified and used for the study (Belz et 
al., 1982; Ching et al., 1991; El-Eraky and Thomas, 2003; Field-
man et al., 1977; Kaukonen et al., 1997; laganiere et al., 1996; 
Min et al., 1996; Olatunde and Price Evans, 1982; Shin et al., 
2007). Characteristics of the clinical studies derived from the 
identified papers are presented in Table 1.
When applicable, data from the selected manuscripts were 
used directly or were derived from the graphs after digitization. 
the latter was done using the GetData Graph Digitizer tool (ht-
tp://www.getdata-graph-digitizer.com).
Simulation study
All simulations were performed using two complementary soft-
ware programs – Simcyp platform version 12 for the in vitro-in 
vivo extrapolation of the ADMe processes (http://www.simcyp.
com) and toxComp version 1.6 (http://www.tox-portal.net) for 
cardiac effect prediction.
Simcyp
the population-based Simcyp Simulator streamlines drug de-
velopment through the modeling and simulation of pharma-
cokinetics (PK) and pharmacodynamics (PD) in virtual popula-
tions. the Simcyp Simulator is the platform for the prediction 
of pharmacokinetic outcomes in clinical populations with the 
use of the human physiology, genetics, and epidemiology infor-
mation. Integration of this information with in vitro data allows 
the prediction of PK drug behavior in “real-world” populations. 
the Simcyp Simulator also can identify key pre-clinical data 
requirements, which are extremely valuable for redefining and 
optimizing early drug development processes and procedures.
ToxComp
toxComp is a user-friendly, systems biology driven, modeling 
and simulation based platform for the proarrhythmic potency 
assessment of chemicals at the population level. the system 
utilizes the in vitro-in vivo extrapolation approach, thus by 
default the input data comes from in vitro ionic current inhi-
bition studies (Polak et al., 2012a). the model describing the 
electrophysiology of the human left ventricular cardiomyocyte, 
applied in the current study, was based on the work reported 
by ten Tusscher et al. (2004), with minor modifications. The 
reasoning behind this selection was that the majority of the data 
used for the model development was of human origin (Nied-
erer et al., 2009). the toxComp system contains a module for 
the virtual population development that is used subsequently as 
a basis for the simulation. Randomly picked individuals carry 
unique demographic and physiological characteristics; the spe-
cific parameters include, inter alia: cardiomyocyte area, electric 
capacitance, and volume (all parameters are age dependent), 
plasma ion concentration, left ventricle heart wall thickness and 
heart rate, with the latter following the circadian rhythm (Polak 
and Fijorek, 2012; Polak et al. 2012b). An additional parameter 
is the genetic status described by potential modification of the 
heRG potassium channel gating parameters (Glinka and Polak, 
2012). Stable version 1.2 currently is available at http://www.
Tab. 1: Characteristics of the clinical study data used for the simulation
Reference n (M/F) Age (years)* Study endpoints Dosing**
El-Eraky and Thomas, 2003 48 (27/21) 33M/31F ΔQTcB Oral (3 mg/kg)
Fieldman et al., 1977 7 (5/2) 23-48 QTcB, ΔQTcB Oral (400 mg)
Olatunde and Price Evans, 1982 7 (4/3) 24.9 (4.76) QTcB, ΔQTcB Oral (400 mg)
Shin et al., 2007 13 (7/6) 26.2 (7.5)M/27.7 (3.6)F QTcB IV infusion (4 mg/kg)
Kaukonen et al., 1997 9 (4/5) 25 (4) QTcB Oral (100 mg)
Min et al., 1996 12 (12/0) 23 (4.3) ΔQTcB Oral (400 mg)
Belz et al., 1982 6 (6/0) 23-33 QTcB Oral (500 mg)
Laganiere et al., 1996 12 (12/0) 24 (5) QTcB Oral (200 mg)
Ching et al., 1991 8 (8/0) 22-29 ΔQTcB Oral (400 mg)
*average (SD) where available or range; ** single dose in all cases
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triggered ionic current modifications. The specific equation, part 
of the ten tusscher model, describing the current of interest was 
multiplied by the inhibition factor calculated with the use of the 
Hill equation (equation 1).
equation 1:   
where:
IC50 – concentration at which the ionic current is inhibited 
by 50%
n – Hill equation parameter
DRUG CONCENTRATION – active drug concentration [µM]
total inhibition was the sum of inhibitions of ionic currents 
triggered by both drugs – quinidine and its metabolite. table 3 
presents the relevant information for both drugs.
the above listed input parameters, which were used to feed 
the appropriate QSAR model, were selected to match the pa-
rameters used during the measurement of different currents. It 
was assumed that neither quinidine nor 3-OH quinidine influ-
ence human physiological parameters, including plasma ion 
concentration and heart rate. two different scenarios were tested 
where either the total, or unbound, concentrations of both com-
pounds were used for the cardiac electric effect simulation and 
compared with the clinically observed data for the pharmacody-
tox-comp.net, either for download or for a live run. this ver-
sion of the platform is freely available and distributed under the 
GNU GPlv3 license.
Pharmacokinetic simulation preceded the heart electrophysi-
ological simulation, and during the latter simulation the same 
group of individuals, carrying the demographic and physiologi-
cal parameters, were involved in the drug pharmacodynamics 
simulation together with the predicted drug plasma concentra-
tion for all virtual individuals involved in the study.
Input data and modeling assumptions
the utilized drug-related input data included two elements, i.e., 
the in vitro information, describing the ADMe processes used 
to run the Simcyp simulation, and the in vitro data describing 
inhibition of various cardiac ionic currents. For the PK simula-
tion, default quinidine (parent) and 3-OH quinidine (main me-
tabolite) compound files were utilized. The major ADME pa-
rameters are listed in table 2, and their values are presented in 
the supplementary materials at www.altex-edition.org. 
the in vitro inhibition of various cardiac ionic currents was 
taken from the literature. If this data was not available, it was 
predicted with previously developed and described QSAR mod-
els (Polak et al., 2011, 2012c,d; Wisniowska et al., 2012). It was 
assumed and confirmed in a subsequent QSAR based simulation 
that 3-OH quinidine also inhibits ionic currents. As multiple re-
sults from various sources were available, those best mimicking 
the human physiology were selected. the IC50 and n values are 
the parameters of the Hill equation used to describe the drug 
Tab. 2: Drug related in vitro ADME data used for quinidine and its main metabolite (3-OH quinidine) in the simulation
Compound Module Model utilized Model parameters 
 Binding B/P (blood-to-plasma ratio),  Default Simcyp values used 
  fu (fraction unbound in plasma) 
 Absorption ADAM model for oral solid formulations Solid formulation where applicable
 Distribution Minimal PBPK model Poulin and Theil method with the Bierezhkovski  
Quinidine
   correction
 Metabolism Enzyme kinetics HLM based data for 3-hydroxylation and N-oxidation
 Elimination Renal clearance Typical renal clearance for a 20- to 30- year-old  
   healthy male (L/h)
 Transport Transporter kinetics on intestinal  Jmax/Km for the apical efflux ABCB1 transporter 
  absorption 
 Binding B/P (blood-to-plasma ratio),  Default Simcyp values used 
  fu (fraction unbound in plasma) 
 Distribution Minimal PBPK model Poulin and Theil method with the Bierezhkovski  
3-OH quinidine   correction
 Metabolism In vivo clearance Default Simcyp CLpo value used
 Elimination Renal clearance Typical renal clearance for a 20- to-30 year-old  
   healthy male (L/h)
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Fig. 1: Plasma concentration prediction
Observed vs. predicted graph and goodness of prediction measures.
Tab. 3: Drug related in vitro data describing cardiac current inhibition for quinidine and its main metabolite (3-OH quinidine)
Ionic current Quinidine [IC50]/n Reference and/or 3-OH quinidine Reference and/or model 
  model input parameters [IC50]/n input parameters
 0.82/1 Kirsch et al., 2004 1.19/1* Polak et al., 2012a:
    Cell: HEK
    Temp: phys
    t1: 2 s
IKr    t2: 2 s
    K+ conc: 5.4 mM
    Holding: -80 mV
    Depolarization: 0 mV
    Measurement: 50 mV
 44/1 Kang et al., 2001 39.67/1* Polak et al., 2012c:
    Cell: HEK (LQT/minK)
IKs    Temp: phys
    t1: 2 s
    Measurement: 20 mV
 10/1 Michel et al., 2002 26.38/1* Wisniowska et al., 2012:
    Cell: Rat VM
    Temp: phys
ICaL    t1: 0.1 s
    Ca2+ conc: 1.8 mM
    Holding: -40 mV
    Depolarization: 0 mV
INa,peak 16.6/1 Mirams et al., 2011 –  –
*QSAR predicted (n – assumed to be 1)
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Fig. 2: Pharmacodynamic 
endpoints ΔQTc and QTc for 
free and total plasma drug 
concentration respectively 
Observed vs. predicted graphs 
and goodness of prediction 
measures.
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Pearson correlation coefficient r and Rescigno ξ2 index in ac-
cordance with the formula presented in equation 2 (Rescigno, 
1992).
equation 2: 
where:
ωj – weight (for this study assumed to be 1)
cr(tj) – observed value (i.e., plasma concentration) in time t
cx(tj) – predicted value (i.e., plasma concentration) in time t
namic endpoints. For all virtual studies the sampling time points 
were repeated, as in the simulated clinical study. If the time of 
day the study commenced was provided, the simulation was set 
to start at the same time. In all other situations, the virtual study 
was assumed to start at 8:00 a.m.
Output and data analysis
Results are presented in the form of the observed versus pre-
dicted graphs for the pharmacokinetic (drug plasma concen-
tration) and pharmacodynamic (either QTc or ΔQTc with 
Bazzet correction applied, or both where applicable) effects. 
the goodness of prediction measures included absolute RMSe 
(absRMSe – root mean squared error over difference between 
maximal and minimal observed value currently analyzed), 
Fig. 3: Total (PRED total) 
and unbound (PRED free) 
drug concentration based 
prediction vs. the observed 
(OBS) ΔQTc values
Effect over time expressed as 
the average values (±SEM).
(continued on next page).
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with the appropriate goodness of prediction measures. Please 
refer to the supplementary materials at www.altex-edition.org 
for the individually presented, detailed results containing an ad-
ditional set of information.
Figure 2 presents the ΔQTcB and QTcB simulation results 
(5 and 6 studies respectively) compared with observed values 
presented in a similar format as above.
the clinical endpoints were compared directly with the pre-
dicted values for all time points characteristic of the clinical 
study protocols. Figure 3 presents a comparison between the 
observed and predicted ΔQTc calculated values based on the 
free and total compound concentrations.
the latter measure is commonly used in the result analysis of 
bioequivalence studies but was applied in this study as a use-
ful measure enabling the comparison of the two curves (in this 
case – predicted and observed for quinidine concentration and 
QTc/ΔQTc change over time).
3  Results
Results presented in Figure 1 contain data from all studies pre-
sented together as a comparison. the observed vs. predicted 
graph for quinidine plasma concentration (all studies) is linked 
Fig. 3: (continued from previous 
page).
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tration. However, considering that the vascular wall is not an 
efficient barrier, the measurement of plasma drug concentra-
tion is a realistic and acceptable surrogate. there are some 
drugs (physico-chemical character) and/or pathophysiological 
(i.e., arteriosclerosis triggered changes in the vascular wall 
permeability) factors that could potentially influence the bal-
ance and change the plasma-to-heart tissue extracellular water 
concentration ratio. Moreover, of greater importance from the 
in silico realized in vitro-in vivo extrapolation perspective is 
to consider the unbound drug as active (driving the pharma-
cological effect). 
In this study both options, total and unbound plasma con-
centrations, were tested and the results are presented. the 
quality of prediction, based on a visual check and the good-
ness of prediction measures analysis, is more accurate for 
the free plasma concentration study arm. Graphical inspec-
tion demonstrates that for the free concentration setup, either 
most (ΔQTcB) or all of the QTcB values for the various time 
points deviate only ±20% from the identity line range. Simu-
lations run in parallel using the total plasma concentration as 
the operational concentration significantly overpredicted the 
cardiac effect. As this cannot be considered as proof, addi-
tional analysis was performed where the observed PD end-
points were directly compared with the predicted values for 
all time points characteristic of the clinical studies protocol. 
the graphs presented in Figure 3 verify the hypothesis and 
show the problems associated with the suitable mimicking of 
the effect over time curve shape. 
For the el-eraky study (el-eraky and thomas, 2003), it was 
noted that the switch from free to total concentration results in 
a drastic increase of the predicted ΔQTc values. Considering 
the relatively low drug concentration values, an increase of 
these values results in a significantly larger IKr current inhibi-
tion as compared to higher concentrations observed in other 
studies, as the concentration points lie on the slope of the Hill 
equation where maximum in vitro change is observed. this 
is subsequently transferred to the simulation and results in a 
large difference between the free and total concentration sce-
narios. Similar effects can be observed for the Olatunde study 
(Olatunde and Price Evans, 1982), where the concentrations 
are comparable to those in the work of el-eraky. there is a dif-
ference of up to 30 ms in the ΔQTc between free and total sce-
narios, although it this connected with an underprediction of 
the plasma concentration in the Olatunde study, which aligns 
and mitigates the PD effect and makes it less spectacular.
The obvious elements that can significantly influence the 
final results are the in vitro current inhibition parameters. In 
this study a mixture of measured and predicted IC50 values 
was utilized. the predicted IC50 values, by default, are bi-
ased by the QSAR model error, but even if we consider the 
superiority of the measured overpredicted values, it still can 
be a source of uncertainty. this is mainly because of the lack 
of standard settings for the in vitro current inhibition studies, 
which generate multiple results depending on the cell line, 
temperature, and other settings applied (Polak et al., 2012e). 
Methodology applied in this work, where the in vitro stud-
4  Discussion
the study was conducted to test the ability to simulate the in 
vivo activity of drugs based exclusively on in vitro data, mim-
icking both the pharmacokinetic and pharmacodynamic arms 
of a clinical study. According to this assumption, the simu-
lation results are presented as both the plasma concentration 
and QTc/ΔQTc change over time. It is worth noting that the 
endpoint choice for a particular simulated study depends ex-
clusively on the data presented in the original paper. Compari-
son between the predicted and observed values of the heart 
rate corrected Qt intervals gives more information relating to 
the quality of the human left ventricular myocyte electrophys-
iology model and its ability to mimic human electrophysiol-
ogy. ΔQTc is more model-independent and gives information 
about the ability of the model to react to factors influencing 
the Qt lengths (in our case – drugs).
Considering that both systems, namely Simcyp for the PK 
simulation and toxComp for the PD simulation, utilized no in 
vivo clinical data, with the exception of the 3-OH quinidine 
Clpo value, which could be replaced either by the whole or-
gan metabolic clearance scaled from the in vitro systems or 
in vitro measured enzyme kinetics, the obtained results are 
consistent with the clinically observed data. 
Analysis of the clinical study results shows one characteris-
tic feature, namely the high heterogeneity of the results, even 
for the studies with relatively similar protocols. the observed 
differences could be a result of the various analytical methods 
applied, sampling times, etc., and may not necessarily reflect 
the real variability. This is an important factor influencing the 
predictivity of the applied methods, which have a tendency 
to underpredict the clinical results. Such an effect is not ob-
vious for the PK endpoint prediction (plasma concentration) 
and ΔQTc from the PD perspective, but it seems to be system-
atic for the Qtc measure. the explanation for this difference 
lies in the characteristics of the model used to describe human 
cardiac myocyte electrophysiology, which tends to underpre-
dict the cardiomyocyte action potential duration. this was 
accounted for at the toxComp system planning level where 
the focus was put on mimicking the human situation and the 
ten tusscher approach (ten tusscher et al., 2004) offered a 
suitable model. However, there are novel models based ex-
clusively on human data, which can help with the under ion 
issue, and their application is planned for the future (O’Hara 
and Rudy, 2011).
As previously mentioned, the verification of viable simula-
tion methodology was one of the additional study goals. the 
author is confident that this is the first published study where 
the utilized methods and techniques were applied in parallel. 
From a practical perspective, the main concern is applying an 
accurate operational drug concentration. two major elements 
need to be considered – drug target (plasma concentration is a 
surrogate for the drug meeting the ionic channels in the heart) 
and binding (free or total concentration). the extracellular wa-
ter in the heart tissue is regarded as the drug target and hence 
the preferred location for measuring the active drug concen-
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5  Conclusions
According to the ICH guidelines for drug studies, cardiac safe-
ty testing in animal models is widely utilized during the test-
ing phase (ICH, 2005). This study proposes a novel concept 
based on a combination of mechanistic PBPK/PD modeling 
and simulation, which could prove invaluable in the predic-
tion of the cardiac effects of drugs and thus help to incorporate 
the 3Rs concept into practice by waiving the current animal 
studies. The presented results illustrate reliable QTc and ΔQTc 
prediction by the combination of the mechanistic IVIVe of the 
PK and PD effects. It can be considered as a proof-of-concept 
that could also be applied as a reliable drug safety evaluation 
procedure.
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